Idiopathic Pulmonary Fibrosis Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Algernon, AstraZeneca, Avalyn, Bellerophon,

February 14 23:44 2023
Idiopathic Pulmonary Fibrosis Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Algernon, AstraZeneca, Avalyn, Bellerophon,
Delveinsight Business Research LLP
The Idiopathic Pulmonary Fibrosis market size in seven major markets was USD 3,167 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 6.6% for the study period (2019–2032). The Idiopathic Pulmonary Fibrosis market is anticipated to grow owing to the expected launch of potential therapies, assisted by an increase in the diagnosed prevalent population in the 7MM.

Companies across the globe are diligently working toward the development of novel treatment therapies, with a considerable amount of success over the years. To date, there are several emerging market players such as, FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., and others that are developing the drug for the treatment of Idiopathic pulmonary fibrosis (IPF).

DelveInsight’s “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Idiopathic Pulmonary Fibrosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Idiopathic Pulmonary Fibrosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Idiopathic Pulmonary Fibrosis Market

Idiopathic Pulmonary Fibrosis: An Overview

The term “idiopathic” refers to a condition with no known cause. Scarring produces stiffness in the lungs, making breathing harder. The most prevalent type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). It is a lung illness that produces scarring (fibrosis).

Scarring produces stiffness in the lungs, making breathing harder. IPF causes irreversible and progressive lung damage, which worsens over time. Certain drugs can help to slow it down in some circumstances. Lung transplantation is occasionally indicated for persons with IPF.

The signs and symptoms of IPF appear gradually and may not show up until the disease has caused significant lung damage. These are likely to deteriorate over time if they occur. Shortness of breath (dyspnea), and dry coughing, which eventually leads to chronic coughing in about 85% of the people with IPF, are some of the most common signs and symptoms of IPF.

Idiopathic Pulmonary Fibrosis Market Key Facts

  • The United States accounts for the largest Idiopathic Pulmonary Fibrosis market size, with approximately USD 2,321 million in 2021, and is expected to increase by 2032.

  • Japan accounted for USD 153 million market share in 2021 i.e., 5% of the total Idiopathic Pulmonary Fibrosis market size in the 7MM.

  • The total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM was 194,800+ in 2021.

  • The highest diagnosed prevalent cases of IPF were accounted for by the US in 2021, with 94,736 cases in the 7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population.

  • Upcoming Idiopathic Pulmonary Fibrosis therapies such as Pamrevlumab, PRM-151 (pentraxin-2, RG6354), Tyvaso (treprostinil), BI 1015550, and others have the potential to create a significant positive shift in the Idiopathic Pulmonary Fibrosis market size.

Idiopathic Pulmonary Fibrosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Idiopathic Pulmonary Fibrosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Idiopathic Pulmonary Fibrosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Idiopathic Pulmonary Fibrosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Idiopathic Pulmonary Fibrosis Epidemiology Segmented by –

  • Total Diagnosed Prevalent Cases of Idiopathic pulmonary fibrosis (IPF) in the 7MM (2019–2032)

  • Gender-specific Diagnosed Prevalent Cases of Idiopathic pulmonary fibrosis (IPF) in the 7MM (2019–2032)

  • Age-specific Diagnosed Prevalent Cases of Idiopathic pulmonary fibrosis (IPF) in the 7MM (2019–2032)

  • Severity-specific Diagnosed Prevalent Cases of Idiopathic pulmonary fibrosis (IPF) in the 7MM (2019–2032)

Idiopathic Pulmonary Fibrosis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to be launched during the study period. The analysis covers the Idiopathic Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Idiopathic Pulmonary Fibrosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Idiopathic Pulmonary Fibrosis Market Will Evolve and Grow by 2032 @

Idiopathic Pulmonary Fibrosis Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Idiopathic Pulmonary Fibrosis. Currently, Hoffmann-La Roche is leading the therapeutics market with its Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage of clinical development. 

The Leading Companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market Include:

Algernon Pharmaceuticals, AstraZeneca, Avalyn Pharmaceuticals, Bellerophon Therapeutics, Boehringer Ingelheim, Bridge Biotherapeutics, Bristol-Myers Squibb, Calliditas Therapeutics, Celgene Pharmaceutical, CSL Behring, Daewoong Pharmaceutical, Endeavor BioMedicines, FibroGen, Galecto Biotech AB, Guangdong Raynovent, Horizon Therapeutics, Insmed, Kadmon Pharmaceuticals, Kinarus AG, Lung Therapeutics, MediciNova, Metagone Biotech, Nitto Denko, Novartis, Pliant Therapeutics, PureTech Health, Regend Therapeutics, Roche, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Syndax Pharmaceuticals, Taiho Pharmaceutical, United Therapeutics, Vicore Pharma, and many more.

Idiopathic Pulmonary Fibrosis Drugs Covered in the Report Include:

  • BI 1015550: Boehringer Ingelheim

  • BMS-986278: Bristol-Myers Squibb

  • C21 (VP01 program): Vicore

  • Garadacimab (previously known as CSL312): CSL Behring

  • GB0139: Galecto Biotech

  • GLPG4716: Galapagos NV

  • HZN-825: Horizon Therapeutics

  • KD025 (Belumosudil): Kadmon Corporation

  • LYT-100 (deupirfenidone): PureTechs

  • MN-001 (tipelukast): MediciNova

  • ND-L02-s0201: Nitto Denko Corporation

  • Pamrevlumab: FibroGen

  • PLN-74809: Pliant Therapeutics

  • PRM-151: Hoffmann-La Roche

  • Tipelukast: MediciNova

  • Tyvaso (inhaled treprostinil): United Therapeutics

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis

4. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

5. Idiopathic Pulmonary Fibrosis Disease Background and Overview

6. Idiopathic Pulmonary Fibrosis Patient Journey

7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Idiopathic Pulmonary Fibrosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Idiopathic Pulmonary Fibrosis Unmet Needs

10. Key Endpoints of Idiopathic Pulmonary Fibrosis Treatment

11. Idiopathic Pulmonary Fibrosis Marketed Products

12. Idiopathic Pulmonary Fibrosis Emerging Drugs and Latest Therapeutic Advances

13. Idiopathic Pulmonary Fibrosis Seven Major Market Analysis

14. Attribute Analysis

15. Idiopathic Pulmonary Fibrosis Market Outlook (In US, EU5, and Japan)

16. Idiopathic Pulmonary Fibrosis Access and Reimbursement Overview

17. KOL Views on the Idiopathic Pulmonary Fibrosis Market

18. Idiopathic Pulmonary Fibrosis Market Drivers

19. Idiopathic Pulmonary Fibrosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Other Trending Healthcare Reports By DelveInsight

Idiopathic Pulmonary Fibrosis Pipeline Insight

“Idiopathic Pulmonary Fibrosis Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States